Pursuant to Regulation 30 of SEBI (LODR) Regulations, 2015, Please find enclosed herewith Investor Presentation for the year ended 31.03.2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Gujarat Terce Laboratories reported FY25 revenue of ₹50.20 crore, up 4.63% YoY, crossing the ₹50 crore mark for the first time. FY25 EBITDA jumped 164% YoY to ₹4.19 crore, with EBITDA margin expanding sharply from 3.31% to 8.35%, signalling a clear operational turnaround. Q4 FY25 revenue grew 1% to ₹12.32 crore and EBITDA rose 5%, but the company posted a reported net loss of ₹3.39 crore, largely due to a one-time deferred tax provision of ₹3.42 crore under the Vivad Se Vishwas Scheme 2024 to settle old tax disputes from FY10–FY14. Cash PAT for FY25 was ₹0.59 crore, marginally lower YoY. Operational wins include collection days falling from 43 to 37, expiry and breakage losses dropping from 2.5% to 1.9%, and zero dependency on borrowings in Q4.
The strong margin expansion and debt-free Q4 suggest improving fundamentals, but the headline Q4 loss driven by a one-time tax settlement may keep the stock volatile in the near term. Investors should track whether the margin gains hold beyond FY25 once the one-off tax charge is digested.